What is SINT's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for SINT.

Stock Ratings / Health Care / SINT / options

CNSY (25) GUTS (34) ICU (31) CTSO (22) ⌘ Pro Terminal →

SiNtx Technologies Inc. (SINT) Options Positioning, Max Pain & Unusual Sweeps

$1.71 +0.59% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.71

SiNtx Technologies Inc. (SINT) carries a Roarable Rating of E (Strong Sell) with 33/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $12.8M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on SINT Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is SINT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, SiNtx Technologies Inc. (NASDAQ: SINT) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $1.71 (+0.59% 1D, market cap $12.8M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 4/20, SEC Balance-Sheet Forensics 11/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, SINT ranks #699 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does SINT compare to CNSY and GUTS in the Health Care sector?

▼

Within the Health Care sector (Medical/Dental Instruments), SINT carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of 45.3%, and ROIC of -35.0%. By comparison, CNSY (Cerenome Inc.) holds a E grade (25/100 RQD, P/E N/A, ROIC -35.0%, cap $12.9M) and GUTS (Fractyl Health Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $13.0M). Among the 5-stock peer group, SINT leads on earnings multiple (N/A) while SINT leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for SINT?

▼

Per SINT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001269026), SiNtx Technologies Inc. generated $1.0M in revenue (-64.7% YoY), -$10.4M in net income, and -$8.8M in free cash flow against $9.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.71 (-0.08%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (33/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.9% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-11.1% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SINT)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (33/100 Composite)

🔍 WHY SINT SCORES 33/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+11/20 pts (33% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9

▲ #2 Bullish Driver: Cash Engine Quality+7/20 pts (21% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 45.3% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$2.07-16.9% Next Q

Q2 (-2Q)

Grade E$1.72-0.6% Next Q

Q3 (-1Q)

Grade E$1.71+0% Next Q

Current

Grade E$1.71-8.9% Hist 90D α

Trajectory: D (41) → E (33)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a SINT Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While SINT currently carries a cautious 33/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.80) and Max Pain ($1.80) forces dealer call-delta covering toward $4.68.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $SINT• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “SINT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 33%NO 67%Trade / Inspect Odds →

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±12.5%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (SINT)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for SINT.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SINT)

✓Walkthrough of SINT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

SINT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -29.34%📐 WEDGE COMPRESSION COIL

2026-11-03O $1.72H $1.72L $1.70C $1.71VOL 4.7K

RES: $2.37SUP: $1.56SMA50: $1.80SMA200: $2.21

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SINT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 SINT Butterfly Map → + Track SINT →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

8.0%/yr Implied 5Y Growth

vs. -64.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on SINT today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for SINT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for SINT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SINT)

Health Care Rank #699 of 1015 ⚔️ CNSY vs SINT Full Matrix →

1. Head-to-Head Health Care Peer Comparison (SINT vs. CNSY, GUTS, ICU, CTSO)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, SiNtx Technologies Inc. (SINT) ranks #699 by composite RQD confidence (33/100, grade E) and #867 by equity capitalization ($12.8M). Within this direct 5-issuer industry benchmark cohort, SINT leads on earnings valuation at N/A trailing P/E, while SINT leads on capital efficiency and profitability with -35.0% ROIC and 45.3% gross margin. GUTS currently holds the highest overall quantitative score in the immediate peer group at 34/100 (E) compared with SINT at 33/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
SINT ACTIVE SiNtx Technologies Inc.	E	33/100	—	45.3%	-35.0%	+0.59%	$12.8M	Benchmark Subject
CNSY Cerenome Inc.	E	25/100	—	—	-35.0%	+0.59%	$12.9M	/cnsy-vs-sint →
GUTS Fractyl Health Inc.	E	34/100	—	—	-35.0%	-3.47%	$13.0M	/guts-vs-sint →
ICU SeaStar Medical Holding Corporation	E	31/100	—	95.7%	-35.0%	-2.23%	$11.8M	/icu-vs-sint →
CTSO Cytosorbents Corporation	E	22/100	—	71.5%	-35.0%	-9.25%	$14.3M	/ctso-vs-sint →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001269026 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), SiNtx Technologies Inc. (SINT) reported GAAP revenue of $1.0M (-64.7% vs. FY2024 revenue of $2.9M , and -61.2% cumulative change since FY2023) , GAAP net income of -$10.4M, operating cash flow of -$8.6M, and free cash flow of -$8.8M (+6.2% YoY). On the balance sheet, SINT closed FY2025 with $9.5M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$1.0M	-$10.4M	-$8.6M	-$8.8M	$9.5M	—
FY2024 (FY)	2024-12-31	$2.9M	-$11.0M	-$8.6M	-$9.3M	$9.4M	—
FY2023 (FY)	2023-12-31	$2.6M	-$8.3M	-$14.1M	-$14.1M	—	—

3. SINT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SINT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does SINT compare to CNSY and GUTS in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for SINT?

Where is SINT trading relative to its 50-day, 200-day, and 52-week technical levels?

SINT last traded at $1.71 (+0.59% on volume of 11,866 shares), positioning the stock -5.00% below its 50-day simple moving average ($1.80) and -22.62% below its 200-day simple moving average ($2.21). Across its 52-week range of $1.40 to $4.46, SINT sits at the 10.1% percentile with a 14-day RSI of 43.4 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.50 to $1.92).

Direct Sub-Reports: SINT RQD Cockpit SINT 12M Forecast SINT Earnings & Move SINT Dividends & DRIP SINT Insiders & 13F SINT Whale Options SINT Profit Sankey SINT News & Why

ROARABLE RATING BRIEF • RQD 33/100 (E) ✓ SEC XBRL & RQD VERIFIED

SINT — SiNtx Technologies Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

SiNtx Technologies Inc. (SINT) earns a live Roarable RQD composite score of 33/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $1.71 (+0.59% 1D, market capitalization $12.8M).

Fundamental Cash Engine (7/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 45.3%, operating margin of -60.0%, and free cash flow yield of —.
Whale 13F & Options Flow (4/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (6/20) + Forensic Balance Sheet (11/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 4/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

SiNtx Technologies Inc. (SINT) is a NASDAQ-listed issuer classified under the Health Care sector and Medical/Dental Instruments industry. Reported revenue across the three fiscal years in the SEC financials ranges from $1.0M to $2.9M, and the company reports a gross margin of 45.3% per the market data.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), SiNtx Technologies Inc. (SINT) reported $1.0M in annual revenue (up from $2.9M in FY2024, -64.7% YoY) and -$10.4M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($2.6M revenue, -$8.3M net income) through FY2025, SINT scaled operating cash flow to -$8.6M and free cash flow to -$8.8M, backed by $9.5M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (E • RQD 33/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 4/20. With Fundamental Cash Engine at 7/20 and Institutional Whale Flow at 4/20, sustained execution supports upside toward the upper end of the $1.40 – $4.46 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are therefore — Investors should note that the absence of mapped links means this analysis cannot identify ripple effects from suppliers, customers, or peer issuers.

Key Question #1: Can SINT sustain or expand its -60.0% operating margin and -35.0% ROIC against Medical/Dental Instruments peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $1.0M and free cash flow of -$8.8M, how will capital allocation balance growth reinvestment against $0 in total debt?
Key Question #3: How sensitive is SINT's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

SINT Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for SiNtx Technologies Inc. (SINT) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to SINT Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 20h ago

What Makes SINTX TECHNOLOGIES (SINT) a New Buy Stock

Yahoo Finance report covering SiNtx Technologies Inc. (SINT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 23h ago

SINTX Technologies nets $2.01M from Class B warrant call, issues 651,204 shares

TradingView report covering SiNtx Technologies Inc. (SINT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE GlobeNewswire • 1d ago

SINTX Technologies Announces Third Quarter 2026 Earnings Release Date and Webcast

GlobeNewswire report covering SiNtx Technologies Inc. (SINT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 1d ago

SINT Q3'26 Earnings: revenue estimate is 1.33M USD

TradingView report covering SiNtx Technologies Inc. (SINT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE https://www.siam.in/ • 1d ago

SiNtx Technologies (SINT) Climbs 3.48% to $1.64 as Shares Press Toward Resistance - PCR Divergence

https://www.siam.in/ report covering SiNtx Technologies Inc. (SINT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingKey • 1d ago

Unusual Volume Stocks & Volume Spikes Today

TradingKey report covering SiNtx Technologies Inc. (SINT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingKey • 1d ago

High Dividend Yield Stocks for Income

TradingKey report covering SiNtx Technologies Inc. (SINT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 20d ago

Transcript: SINTX Technologies Q2 2026 Earnings Conference Call

SINTX Technologies (NASDAQ:SINT) held its second-quarter earnings conference call on Tuesday. Below is the complete transcript from the call. This transcript is brought to you by Benzinga APIs. For real-time access to

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

SINT Bull vs. Bear Conversation Board — What's Your Call at $1.71?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON SINT 🐻 33% BEARISH CONVICTION

MI MidwestValue RQD DEBATE OPENER • Fundamental Long-Only 🐂 BULLISH 🎯 Target: $2.12 (+24.7%)

📌 Pinned Debate

Balance sheet pillar scores 11/20 with an Altman Z of 2.5 and Debt/Equity of 0.5, the strongest component of the RQD rating.

Don't sleep on SINT's setup in Health Care. Balance sheet pillar scores 11/20 with an Altman Z of 2.5 and Debt/Equity of 0.5, the strongest component of the RQD rating.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (33/100) backs up the fundamental quality.

CapAlloc_Nerd 🐂 BULL

@RiskArb_Desk Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Medical/Dental Instruments. If gross margin (45.3%) holds, EPS grows into the multiple faster than bears think.

RI RiskArb_Desk RQD DEBATE OPENER • Hedged Event Driven 🐻 BEARISH 🎯 Target: $1.31 (-22.9%)

Spot @ $1.70

ROIC of -35%, a 0% FCF yield, and FY 2025 revenue down to $1.0M from $2.9M show no current cash generation.

I respect the product at SiNtx Technologies Inc., but the stock at $1.70 is a different story. ROIC of -35%, a 0% FCF yield, and FY 2025 revenue down to $1.0M from $2.9M show no current cash generation.. FCF yield is 0.0% and RQD sits at 33/100 (E) — why pay up here when you can wait for next quarter's numbers?